Ucb Sa: (OTC: UCBJF)
$60.00
-1.08 (-1.77%)
Volume 104
May 08 10:11 AM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 60.00 - 60.00 |
| 52wk Low - High | 48.35 - 63.84 |
| Previous Close | 61.08 |
| Avg. Volume | 5 |
| Industry | MED-DRUGS |
| Market Cap | 11.01 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.37 |
| PE (Forward) | 23.81 |
| Current Year Est. | 2.52 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
108 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 23.81 |
| PEG Ratio | 1.98 |
| Current Year Est. | 2.52 |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | NA |
| EPS Last Year | NA |
| Expected Earnings Growth | 12.00% |
Company Description
UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson's disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (03/2013) |
Next Qtr (06/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | 2.52 | 3.09 |
| Number of Estimates | 0 | 0 | 2 | 2 |
| Low Estimate | NA | NA | 2.46 | 3.01 |
| High Estimate | NA | NA | 2.58 | NA |
| Year Ago EPS | NA | NA | NA | 2.52 |
| EPS Growth | NA | NA | NA | 22.62% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| UCB SA | UCBJF | 60.00 | |
|
| JAZZ PHARMACEUT | JAZZ | 60.00 | |
|
| SALIX PHARM-LTD | SLXP | 59.33 | |
|
| SANTARUS INC | SNTS | 22.30 | |
|
| USANA HLTH SCI | USNA | 67.95 | |
|
| BIOCRYST PHARMA | BCRX | 1.70 | |
|
| CATALYST PHARMA | CPRX | 0.91 | |
|
| CELL THERAPEUT | CTIC | 1.32 | |
|
| CUBIST PHARM | CBST | 55.46 | |
|
| ELAN CP PLC ADR | ELN | 12.07 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Nektar Posts Wider Loss, Maintains View
May 15, 2013
Questcor Misses on Earnings, Revs
May 03, 2013
Valeant Beats Earnings, Misses Revs
May 03, 2013
Shire Beats Earnings in 1Q
May 03, 2013
Glaxo's Trametinib Delayed
May 02, 2013
ViroPharma Reports Loss in 1Q
May 02, 2013
Actavis Beats on Earnings, Raises View
May 02, 2013
Loss Widens at Momenta
May 02, 2013
Financials
| EPS TTM | NA |
| Sales | NA |
| Net Income | NA |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
The Zacks Analyst Blog Highlights: Chicago Bridge & Iron, Shire, Actavis, UCB and WuXi PharmaTech - Pr Newswire
May 2, 2013
Data from Novartis' SPARK - Zacks.Com
Apr 24, 2013
Pipeline Progresses at ViroPharma - Zacks.Com
Apr 24, 2013
The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB - Pr Newswire
Apr 19, 2013
UCB SA/NV - Convocation to the Annual General Shareholders' meeting - Thomson Reuters One
Mar 26, 2013
UCB and Five Prime enter into strategic discovery collaboration - Datamonitor
Mar 23, 2013
UCB licenses rights to tozadenant from Biotie Therapies - Datamonitor
Mar 7, 2013
UCB files for marketing authorization for arthritis drug with FDA and EMA - Datamonitor
Feb 28, 2013
Broker Recommendations
| Current ABR | 3.50 |
| ABR (Last Week) | 3.50 |
| # of recs in ABR | 2 |
| Average Target Price | NA |
| Industry Rank by ABR | 108 out of 265 |
| Rank in Industry | 16 out of 93 |
